Ablynx And Merck Enter Immune Checkpoint Blocker Nanobody Pact
This article was originally published in The Pink Sheet Daily
Executive Summary
Ablynx and Merck & Co have expanded their ties by creating a new research alliance aimed at developing predefined nanobody candidates, including bi- and tri-specifics, directed at immune checkpoint modulators involved in cancer.